- Phase 3 trial results: mRNA-1273 vaccine continued to be safe and efficacious more than five months after second dose http://dx.doi.org/10.1056/nejmoa2113017 24 comments science
Linked pages
- Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2109522 1533 comments
- https://www.nejm.org/doi/pdf/10.1056/NEJMoa2101765?articleTools=true 528 comments
- Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2208375 145 comments
- Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons | NEJM https://www.nejm.org/doi/full/10.1056/nejmoa2104983 38 comments
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine | NEJM https://www.nejm.org/doi/full/10.1056/nejmoa2035389 18 comments
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://www.nejm.org/doi/10.1056/nejmoa2034201 4 comments
- Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2205650 3 comments
- https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1 1 comment
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2034577 1 comment
- Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants | NEJM https://www.nejm.org/doi/full/10.1056/NEJMc2104974 0 comments
Related searches:
Search whole site: site:dx.doi.org
Search title: Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase | NEJM
See how to search.